Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-02-06
DOI
10.1038/s41416-020-0743-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Plasticity of myeloid-derived suppressor cells in cancer
- (2018) Evgenii Tcyganov et al. CURRENT OPINION IN IMMUNOLOGY
- Enhanced CD40 and ICOSL expression on dendritic cells surface improve anti-tumor immune responses; effectiveness of mRNA/chitosan nanoparticles
- (2018) Saeed Daneshmandi et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- Myeloid-derived suppressor cell accumulation in renal cell carcinoma is correlated with CCL2, IL-17 and IL-18 expression in blood and tumors
- (2018) XIAODONG GUAN et al. Advances in Clinical and Experimental Medicine
- Ibrutinib treatment improves T cell number and function in CLL patients
- (2017) Meixiao Long et al. JOURNAL OF CLINICAL INVESTIGATION
- Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia
- (2017) Qingsong Yin et al. JOURNAL OF IMMUNOLOGY
- STAT1 gene deficient mice develop accelerated breast cancer growth and metastasis which is reduced by IL-17 blockade
- (2017) Sanjay Varikuti et al. OncoImmunology
- Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment
- (2016) Andrew Stiff et al. CANCER RESEARCH
- Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth
- (2016) Jun Chen et al. MOLECULAR CANCER THERAPEUTICS
- Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Dendritic Cells and Cancer Immunity
- (2016) Alycia Gardner et al. TRENDS IN IMMUNOLOGY
- The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
- (2016) Vinit Kumar et al. TRENDS IN IMMUNOLOGY
- Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
- (2016) Vincenzo Bronte et al. Nature Communications
- A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells
- (2016) Gayathri Natarajan et al. OncoImmunology
- Tumor-Infiltrating Dendritic Cells in Cancer Pathogenesis
- (2015) Jo Marie Tran Janco et al. JOURNAL OF IMMUNOLOGY
- Inhibition of the kinase ITK in a mouse model of asthma reduces cell death and fails to inhibit the inflammatory response
- (2015) Yonglian Sun et al. Science Signaling
- Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer
- (2015) A. J. Gunderson et al. Cancer Discovery
- Inhibition of the kinase ITK in a mouse model of asthma reduces cell death and fails to inhibit the inflammatory response
- (2015) Yonglian Sun et al. Science Signaling
- Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells
- (2015) Gayathri Natarajan et al. OncoImmunology
- Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients
- (2015) Caroline Bergenfelz et al. PLoS One
- Two targets for the price of one
- (2013) S. M. Ansell BLOOD
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
- (2013) J. A. Dubovsky et al. BLOOD
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Th17/IL-17A Might Play a Protective Role in Chronic Lymphocytic Leukemia Immunity
- (2013) Iwona Hus et al. PLoS One
- A role for CCL2 in both tumor progression and immunosurveillance
- (2013) Ming Li et al. OncoImmunology
- Impact of Sleep as a Specific Marker of Quality of Life in Allergic Rhinitis
- (2012) Vanesa González-Núñez et al. CURRENT ALLERGY AND ASTHMA REPORTS
- Tyrosine Kinase Btk Is Required for NK Cell Activation
- (2012) Yan Bao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia
- (2012) Farhad Jadidi-Niaragh et al. TUMOR BIOLOGY
- Dendritic cell control of tolerogenic responses
- (2011) Santhakumar Manicassamy et al. IMMUNOLOGICAL REVIEWS
- MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy
- (2011) James Finke et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- A Novel Role for Bruton's Tyrosine Kinase in Hepatocyte Growth Factor-mediated Immunoregulation of Dendritic Cells
- (2011) Eshu Singhal et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells
- (2011) Mercedes B. Fuertes et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model
- (2011) C. Meyer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia
- (2010) K. Fiedler et al. BLOOD
- Tyrosine kinase Btk regulates E-selectin-mediated integrin activation and neutrophil recruitment by controlling phospholipase C (PLC) 2 and PI3K pathways
- (2010) H. Mueller et al. BLOOD
- Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination
- (2010) Anamika Bose et al. INTERNATIONAL JOURNAL OF CANCER
- Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity
- (2008) K. Movahedi et al. BLOOD
- Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy
- (2008) C. Marcela Diaz-Montero et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Behavior of immune players in the tumor microenvironment
- (2008) Mikael J Pittet CURRENT OPINION IN ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now